The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global gastrointestinal therapeutics market grew at a CAGR of around 7% during 2015-2020. Gastrointestinal (GI) syndrome refers to a medical ailment that affects the functioning of organs in the digestive tract. It impacts the stomach, pancreas, small and large intestines, gall bladder and liver and is usually characterized by indigestion, heartburn, constipation and bloating. Some of the commonly used GI therapeutics include prescription and over-the-counter (OTC) drugs, such as antacids, laxatives, antidiarrheal agents, antiemetics, antiulcer agents, and endoscopic and radiological procedures and hematological tests. These therapeutics assist in the detection of the disorder and absorbing nutrients from the food to improve digestion, regulate water flow in the GI system and minimize gastric acidity.
The increasing prevalence of GI diseases, such as inflammatory bowel disease (IBD) and ulcerative colitis, is one of the key factors driving the growth of the market. Due to changing lifestyle patterns and unhealthy dietary habits, there is an increased probability of disease recurrence among patients across the globe. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Various technological advancements, such as the development of innovative biosimilars and cellular therapies for the treatment of the disorder, are acting as other growth-inducing factors. These biologics are administered through intravenous and subcutaneous injections and are personalized for targeted treatments. Other factors, including rising health consciousness among the masses, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, especially in developing economies, are anticipated to drive the market further. Looking forward, IMARC Group expects the global gastrointestinal therapeutics market to exhibit moderate growth during the next five years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global gastrointestinal therapeutics market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, route of administration, application and distribution channel.
Breakup by Type:
Breakup by Route of Administration:
Breakup by Application:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceuticals.
Infantile Spasms Therapeutics Market by Therapeutic Class (Anticonvulsants, Corticosteroids, and Others), Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others (Phase III)), Dosage (Solid, Liquid), Route of Administration (Oral, Parenteral, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Hospitals, Clinics, and Others), and Region 2023-2028
Hyperphosphatemia Drugs Market by Product (Sevelamer, Calcium Based Phosphate Binders, Iron Based Phosphate Binders, Lanthanum Carbonate, and Others), Dosage Form (Tablets, Syrups, Capsules), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Urology Robotic Surgery Market by Component (Robotic Surgery Systems, Instruments and Accessories, Services), Application (Robotic Prostatectomy, Robotic Cystectomy, Robotic Pyeloplasty, Robotic Nephrectomy, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at